Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP)

Peter Schuld, PhD, Stephan Grzesiek, PhD, Johannes Schlotte, Judith M Habazettl, PhD, Wolfgang Jahnke, PhD, Louise Barys, MS, Sandra W Cowan-Jacob, PhD, Alice Loo, MS, Andrea Wiget, Paul W. Manley, PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-140968

Published: 2020

Journal Articles

Fingolimod (FTY720) Inhibits BCR-ABL Signaling Allosterically by Binding to the Myristate Binding Site

Paul W. Manley, Ph. D., Sandra W. Cowan-Jacob, Robert Cozens, Gabriele Fendrich, Wolfgang Jahnke, Johannes L Roesel, Doriano Fabbro

Blood (2011) 118 (21): 2746.

https://doi.org/10.1182/blood.V118.21.2746.2746

Published: 2011

Journal Articles

Nilotinib, in Comparison to Both Dasatinib and Imatinib, Possesses a Greatly Prolonged Residence Time When Bound to the BCR-ABL Kinase SH1 Domain

Paul W. Manley, Ph. D., Sandra W. Cowan-Jacob, Gabriele Fendrich, Wolfgang Jahnke, Doriano Fabbro

Blood (2011) 118 (21): 1674.

https://doi.org/10.1182/blood.V118.21.1674.1674

Published: 2011

Journal Articles

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Arghya Ray, Sandra W. Cowan-Jacob, Paul W. Manley, Jürgen Mestan, James D. Griffin

Blood (2007) 109 (11): 5011–5015.

https://doi.org/10.1182/blood-2006-01-015347

Published: 2007

Includes: Supplemental data

Journal Articles

Bcr-Abl Binding Modes of Dasatinib, Imatinib and Nilotinib: An NMR Study.

Paul W. Manley, Sandra W. Cowan-Jacob, Gabriele Fendrich, André Strauss, Navratna Vapai, Stephan Grzesiek, Wolfgang Jahnke

Blood (2006) 108 (11): 747.

https://doi.org/10.1182/blood.V108.11.747.747

Published: 2006

Journal Articles

Molecular Interactions between the Highly Selective pan-Bcr-Abl Inhibitor, AMN107, and the Tyrosine Kinase Domain of Abl.

Paul W. Manley, Sandra W. Cowan-Jacob, Gabriele Fendrich, Jürgen Mestan

Blood (2005) 106 (11): 3365.

https://doi.org/10.1182/blood.V106.11.3365.3365

Published: 2005

NARROW

Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP)

Fingolimod (FTY720) Inhibits BCR-ABL Signaling Allosterically by Binding to the Myristate Binding Site

Nilotinib, in Comparison to Both Dasatinib and Imatinib, Possesses a Greatly Prolonged Residence Time When Bound to the BCR-ABL Kinase SH1 Domain

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Bcr-Abl Binding Modes of Dasatinib, Imatinib and Nilotinib: An NMR Study.

Molecular Interactions between the Highly Selective pan-Bcr-Abl Inhibitor, AMN107, and the Tyrosine Kinase Domain of Abl.

Email alerts

ASH Publications

American Society of Hematology

Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP)

Fingolimod (FTY720) Inhibits BCR-ABL Signaling Allosterically by Binding to the Myristate Binding Site

Nilotinib, in Comparison to Both Dasatinib and Imatinib, Possesses a Greatly Prolonged Residence Time When Bound to the BCR-ABL Kinase SH1 Domain

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Bcr-Abl Binding Modes of Dasatinib, Imatinib and Nilotinib: An NMR Study.

Molecular Interactions between the Highly Selective pan-Bcr-Abl Inhibitor, AMN107, and the Tyrosine Kinase Domain of Abl.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only